Head to Head Analysis: TherapeuticsMD (NASDAQ:TXMD) & Can-Fite BioPharma (NYSE:CANF)

Can-Fite BioPharma (NYSE:CANF) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk and profitability.

Valuation and Earnings

This table compares Can-Fite BioPharma and TherapeuticsMD”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405,000.00	5.28	-$7.63 million	($14.80)	-0.14
TherapeuticsMD	$3.27 million	7.11	-$570,000.00	$0.02	100.50

TherapeuticsMD has higher revenue and earnings than Can-Fite BioPharma. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Can-Fite BioPharma has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Can-Fite BioPharma and TherapeuticsMD, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0	1	2	0	2.67
TherapeuticsMD	1	0	0	0	1.00

Can-Fite BioPharma presently has a consensus target price of $44.00, suggesting a potential upside of 2,100.00%. Given Can-Fite BioPharma’s stronger consensus rating and higher probable upside, research analysts plainly believe Can-Fite BioPharma is more favorable than TherapeuticsMD.

Institutional & Insider Ownership

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Can-Fite BioPharma and TherapeuticsMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
TherapeuticsMD	-6.64%	-1.09%	-0.78%

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.